Competing interests
Cancer
CANCER
LSK Biopharma / Elevar Therapeutics provided funding support for the current study directly to Huntsman Cancer Institute. University of Utah provided funding for some correlative studies included in the present manuscript. SG has received honoraria from SITC advances in Cancer Immunotherapy as the Salt Lake City Program Organizer and presenter, travel support from QED Biopharmaceutical, as well as funding for other clinical trials from Bristol Myers Squibb, Rexahn, Incyte, Novartis, LSK, Five Prime, Mirati, QED, Debiopharm, Merck, Pfizer, Astra Zeneca, Medimmune, Clovis, Immunocore, and Seattle Genetics. All other authors have no relevant competing interests.